Want to see CARM full AI Analyst Report?
Carisma Therapeutics (CARM) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ct-0525 | Her2-Positive | Phase I | Active Not Recruiting | CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors | Feb 02, 2024 | ― |
| Pembrolizumab, Ct-0508 | Prostate Cancer, Bladder Cancer, Ovarian Neoplasms, Colorectal Cancer, Breast Cancer, Cancer, Pancreatic Cancer, Endometrial Cancer, Head And Neck Cancer, Her2-Positive Breast Cancer, Her2-Positive Gastric Cancer, Biliary Tract Cancer, Carcinoma, Squamous, Adenocarcinoma, Lung Cancer, Small Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Carcinoma, Transitional Cell, Breast Neoplasm, Carcinoma, Small Cell, Esophagogastric Junction Neoplasms, Her-2 Protein Overexpression, Her2-Positive, Bile Duct Cancer, Carcinoma, Ductal, Lung Cancer, Non-Small-Cell, Carcinoma, Ovarian Epithelial, Inflammatory Breast Cancer, Malignant Neoplasms, Her2-Positive Solid Tumors, Her-2 Gene Amplification | Phase I | Active Not Recruiting | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | Nov 23, 2020 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Ct-0525 | Phase I | Her2-Positive | Active Not Recruiting | CAR-monocytes for the Treatment of HER2 Overexpressing Solid Tumors | Feb 02, 2024 | ― |
| Pembrolizumab, Ct-0508 | Phase I | Prostate Cancer, Bladder Cancer, Ovarian Neoplasms, Colorectal Cancer, Breast Cancer, Cancer, Pancreatic Cancer, Endometrial Cancer, Head And Neck Cancer, Her2-Positive Breast Cancer, Her2-Positive Gastric Cancer, Biliary Tract Cancer, Carcinoma, Squamous, Adenocarcinoma, Lung Cancer, Small Cell, Carcinoma, Hepatocellular, Stomach Neoplasms, Carcinoma, Transitional Cell, Breast Neoplasm, Carcinoma, Small Cell, Esophagogastric Junction Neoplasms, Her-2 Protein Overexpression, Her2-Positive, Bile Duct Cancer, Carcinoma, Ductal, Lung Cancer, Non-Small-Cell, Carcinoma, Ovarian Epithelial, Inflammatory Breast Cancer, Malignant Neoplasms, Her2-Positive Solid Tumors, Her-2 Gene Amplification | Active Not Recruiting | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | Nov 23, 2020 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Carisma Therapeutics, Inc. (CARM) have in its pipeline
Carisma Therapeutics CARM is currently developing the following drugs: Ct-0525, Pembrolizumab, Ct-0508. These drug candidates are in various stages of clinical development as the company works toward FDA approval.